SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharma gets tentative USFDA’s nod for breast cancer drug

01 Apr 2024 Evaluate

Alembic Pharmaceuticals has received tentative approval for generic Ribociclib tablets used in the treatment of breast cancer in the March quarter. The tentative approval by the US Food & Drug Administration (USFDA) was for Ribociclib tablets of strength 200 mg. 

The medicine is indicated for the treatment of adult patients with a certain type of advanced or metastatic breast cancer in a combination of drug therapy. It is the generic equivalent of Novartis' Kisqali tablets.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

765.55 2.00 (0.26%)
22-Apr-2026 09:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1662.75
Dr. Reddys Lab 1211.30
Cipla 1224.65
Zydus Lifesciences 925.75
Lupin 2290.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×